Actinogen issues director placement shares after shareholder approval

An update from Actinogen Medical ( (AU:ACW) ) is now available.

Actinogen Medical has issued 15,880,953 new fully paid ordinary shares at $0.042 each to its directors, following shareholder approval of a director placement earlier in March. The company confirmed it has met its continuous disclosure and financial reporting obligations, and that no excluded information exists under the Corporations Act in relation to the new shares, allowing the securities to trade without a prospectus and reinforcing governance transparency for investors.

The placement modestly strengthens Actinogen’s capital position as it advances clinical development of Xanamem for Alzheimer’s disease and other cortisol-linked conditions. By completing the director placement on a cleansed basis, the company preserves flexibility in its funding strategy while signalling board-level commitment to its long-term drug development programs and ongoing trials in Australia and the U.S.

The most recent analyst rating on (AU:ACW) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Its lead compound, Xanamem, is being developed primarily for Alzheimer’s disease, with additional work in depression and potential future studies in Fragile X Syndrome and other brain disorders.

Average Trading Volume: 4,677,205

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$125.1M

For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.